MD
Molbio Diagnostics Limited IPO
Molecular Diagnostics · Point-of-Care (POC) · Truenat Platform · Healthcare
📋 Mainline IPO
Fresh + OFS
NSE, BSE
₹807
Upper Price
₹939.70 Cr
Issue Size
Aug 17, 2026
Listing Date
₹9,099.71 Cr
Market Cap (Pre)
📅 IPO Timetable
All dates tentative🟢
IPO Opens
Monday, 10 August 2026
Bidding starts — apply before close
🔒
IPO Closes
Wednesday, 12 August 2026
Last day to bid — closes at 5:00 PM IST
📊
Basis of Allotment
Thursday, 13 August 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Friday, 14 August 2026
Unallotted funds returned; shares credited to demat
🏷️
Monday, 17 August 2026
Trading begins from 10:00 AM IST
📋 IPO Details
IPO Open Date10 August 2026 (Mon)
IPO Close Date12 August 2026 (Wed)
Listing Date17 August 2026 (Mon)
Face Value₹1 per share
Price Band₹768 to ₹807
Issue Price (Upper Band)₹807 per share
Issue TypeBook Build — Fresh + OFS
Lot Size18 shares
Total Issue Size1,16,46,246 shares (₹939.70 Cr)
Fresh Issue24,80,246 shares (₹200.00 Cr)
Offer for Sale (OFS)91,66,000 shares (₹739.70 Cr)
Pre-Issue Shares11,27,59,750
Post-Issue Shares11,52,39,996
Promoter Holding (Pre)46.65%
Market Cap (Pre-IPO)₹9,099.71 Cr
Listing ExchangeNSE, BSE
Lead ManagerKotak, IIFL, Jefferies, Motilal Oswal
RegistrarKfin Technologies Ltd.
💰 Lot Size & Minimum Investment
At upper price ₹807| Investor Type | Lots | Shares | Amount |
|---|---|---|---|
| Retail — Minimum | 1 | 18 | ₹14,526 |
| Retail — Maximum | 13 | 234 | ₹1,88,838 |
| S-HNI (sNII) — Min | 14 | 252 | ₹2,03,364 |
| S-HNI (sNII) — Max | 68 | 1,224 | ₹9,87,768 |
| B-HNI (bNII) — Min | 69 | 1,242 | ₹10,02,294 |
⚠️ Note: Investors can bid for a minimum of 18 shares and in multiples thereof. Retail individual investors can apply up to ₹2,00,000. Employee discount of ₹76.00 per share is applicable.
👥 Investor Reservation
Allocated portion of Net OfferNot more than 50%
QIB Portion
Not less than 35%
Retail Portion
Not less than 15%
NII Portion
📊 Subscription Status
Loading…
📈 Company Financials
Restated Consolidated · ₹ Crore| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| PAT | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves & Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Income Growth
FY 2023–24₹840.66 Cr
FY 2024–25₹1,027.94 Cr
FY 2025–26₹1,455.17 Cr
🎯 Key Performance Indicators
15.59%
ROE
FY 2025–26
0.36
Debt/Equity
FY 2025–26
17.55%
ROCE
FY 2025–26
11.28%
PAT Margin
FY 2025–26
22.56%
EBITDA Margin
FY 2025–26
14.55%
RoNW
FY 2025–26
9.55x
Price/Book
FY 2025–26
Truenat
POC Platform
Proprietary Technology
⚖️ Valuation & EPS
Pre-IPO EPS
₹14.56
FY26 earnings + pre-issue shares
P/E: 55.43xPost-IPO EPS
₹14.24
FY26 earnings + post-issue shares
P/E: 56.67xPrice to Book Value
9.55x
At upper price band ₹807
Market Cap (Pre-IPO)
₹9,099.71 Cr
At issue price ₹807
ℹ️
Pre-IPO EPS (₹14.56) based on pre-issue shares (11,27,59,750) and FY26 earnings. Post-IPO EPS (₹14.24) includes the dilution metrics derived from post-issue total equity capital of 11,52,39,996 shares following the 24,80,246 fresh equity issuance block. Post-IPO Market Cap expands to ₹9,299.87 Cr.
🎯 Objects of the Issue
Net proceeds utilisation1
Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
₹125.12 Cr
2
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
₹80.81 Cr
3
General Corporate Purposes
Balance
Total Fresh Issue Goal
₹200.00 Cr
🏢 About Molbio Diagnostics Ltd.
Est. 2000 · Goa · Molecular DiagnosticsMolbio Diagnostics Limited, incorporated in October 2000, is a highly advanced global point-of-care (POC) molecular diagnostics pioneer specializing aggressively in the research, engineering, and rapid commercialization of testing solutions for infectious and non-communicable diseases. The company is globally celebrated for its proprietary ‘Truenat’ platform—a highly portable, battery-operated PCR-based molecular diagnostics ecosystem designed specifically for resource-limited environments, delivering definitive clinical results in under an hour.
The business maintains massive technological moats with molecular testing solutions addressing over 30 diseases via 43 highly targeted diagnostic assays covering Tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. Backed by 1,225 permanent personnel, Molbio operates 6 massive localized manufacturing installations across India and serves active clinical and governmental pipelines stretching across 90+ countries, deeply embedding itself within institutional healthcare infrastructures worldwide.
Brand Ecosystem
🔬
Truenat Platform
WHO-endorsed portable, battery-operated PCR testing hardware providing rapid, accurate POC results
🧪
Diagnostic Assays
Broad molecular testing suite covering 30+ diseases via 43 distinct testing pipelines
🏭
Global Distribution
Commercial sales networks spanning 90+ countries supplying governments and international labs
🏥
Clinical Capabilities
Strategic subsidiaries executing complex radiology, digital pathology, and breast health screening
Competitive Strengths
🏆Proprietary Truenat platform featuring highly exclusive WHO-endorsed TB molecular diagnostic tech
💡Formidable R&D intelligence heavily insulated by an extensive, high-barrier global patent portfolio
💰Highly scalable business architecture generating tremendous recurring revenues via diagnostic test kits
🌍Dominant international presence actively supplying institutional networks across 90+ countries
Company Promoters
CN
Chandrasekhar Bhaskaran Nair & Sriram Natarajan
Promoters, Molbio Diagnostics Ltd.
ET
Exxora Trading LLP
Promoter Entity, Molbio Diagnostics Ltd.
📅 Key Dates
IPO Opens10 Aug 2026
IPO Closes12 Aug 2026
Allotment13 Aug 2026
Refund & Share Credit14 Aug 2026
Listing Day17 Aug 2026
💡 Quick Summary
Price Band₹768 – ₹807
Upper Price₹807 / share
Lot Size18 shares
Min. Investment (Retail)₹14,526
Issue Size₹939.70 Cr
ListingBSE, NSE
🏦 Registrar & Lead Manager
Lead Manager
Kotak, IIFL, Jefferies, Motilal Oswal
📍 Registered Address
Molbio Diagnostics Ltd.
Plot No. L-46, Phase II-D,
Verna Industrial Area, Salcete,
South Goa, Goa — 403722
📞 8326724888
[email protected]
Plot No. L-46, Phase II-D,
Verna Industrial Area, Salcete,
South Goa, Goa — 403722
📞 8326724888
[email protected]
🛡️ Regulatory Note: Mainline IPO investments are subject to SEBI regulations. Always read the Prospectus/RHP before applying. Consult a SEBI-registered advisor before investing.
⚠️
Disclaimer: This page presents publicly available information from the Molbio Diagnostics IPO RHP for informational purposes only. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Molbio Diagnostics IPO 2026: Price Band, GMP, Subscription, Lot Size, Dates & Review GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →